Iodinated Copper–Cysteamine Nanoparticles as Radiosensitizers for Tumor Radiotherapy

Background/Objectives: Radiotherapy is a widely applied first-line clinical treatment modality of cancer. Copper–cysteamine (Cu-Cy) nanoparticles represent a new type of photosensitizer that demonstrates significant anti-tumor potential by X-ray-induced photodynamic therapy. Iodide is a high-Z eleme...

Full description

Saved in:
Bibliographic Details
Published inPharmaceutics Vol. 17; no. 2; p. 149
Main Authors Zhang, Miaomiao, Yang, Yu, Xu, Ying, Wang, Jie, Li, Shihong
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 22.01.2025
MDPI
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Background/Objectives: Radiotherapy is a widely applied first-line clinical treatment modality of cancer. Copper–cysteamine (Cu-Cy) nanoparticles represent a new type of photosensitizer that demonstrates significant anti-tumor potential by X-ray-induced photodynamic therapy. Iodide is a high-Z element with superior X-ray absorption ability and has the β-decay radiotherapeutic nuclide, 131I, which emits Cherenkov light. In this study we aimed to investigate the X-ray-induced photodynamic therapy potential of iodinated Cu-Cy (Cu-Cy-I) nanoparticles and also explore the local treatment efficacy of 131I-labeled Cu-Cy-I ([131I]Cu-Cy-I) nanoparticles. Methods: The synthesis of [131I]Cu-Cy-I nanoparticles was performed with [131I]I− anions. The in vitro radiobiological effects on tumor cells incubated with Cu-Cy-I nanoparticles by X-ray irradiation were investigated. The in vivo tumor growth-inhibitory effects of the combination of Cu-Cy-I nanoparticles with X-ray radiotherapy and [131I]Cu-Cy-I nanoparticles were evaluated with 4T1 tumor-xenografted mice. Results: The in vitro experiment results indicated that the X-ray irradiation with the presence of Cu-Cy-I nanoparticles produced a higher intracellular reactive oxygen species (ROS) level and more DNA damage of 4T1 cells and showed a stronger tumor cell killing ability compared to X-ray irradiation alone. The in vivo experimental results with 4T1 breast carcinoma-bearing mice showed that the combination of an intratumoral injection of Cu-Cy-I nanoparticles and X-ray radiotherapy enhanced the tumor growth-inhibitory effect and prolonged the mice’s lives. Conclusions: Cu-Cy-I nanoparticles have good potential as new radiosensitizers to enhance the efficacy of external X-ray radiotherapy. However, the efficacy of local treatment with [131I]Cu-Cy-I nanoparticles at a low 131I dose was not verified. The effective synthesis of smaller sizes of nanoparticles is necessary for further investigation of the radiotherapy potential of [131I]Cu-Cy-I nanoparticles.
AbstractList Background/Objectives: Radiotherapy is a widely applied first-line clinical treatment modality of cancer. Copper–cysteamine (Cu-Cy) nanoparticles represent a new type of photosensitizer that demonstrates significant anti-tumor potential by X-ray-induced photodynamic therapy. Iodide is a high-Z element with superior X-ray absorption ability and has the β-decay radiotherapeutic nuclide, 131I, which emits Cherenkov light. In this study we aimed to investigate the X-ray-induced photodynamic therapy potential of iodinated Cu-Cy (Cu-Cy-I) nanoparticles and also explore the local treatment efficacy of 131I-labeled Cu-Cy-I ([131I]Cu-Cy-I) nanoparticles. Methods: The synthesis of [131I]Cu-Cy-I nanoparticles was performed with [131I]I− anions. The in vitro radiobiological effects on tumor cells incubated with Cu-Cy-I nanoparticles by X-ray irradiation were investigated. The in vivo tumor growth-inhibitory effects of the combination of Cu-Cy-I nanoparticles with X-ray radiotherapy and [131I]Cu-Cy-I nanoparticles were evaluated with 4T1 tumor-xenografted mice. Results: The in vitro experiment results indicated that the X-ray irradiation with the presence of Cu-Cy-I nanoparticles produced a higher intracellular reactive oxygen species (ROS) level and more DNA damage of 4T1 cells and showed a stronger tumor cell killing ability compared to X-ray irradiation alone. The in vivo experimental results with 4T1 breast carcinoma-bearing mice showed that the combination of an intratumoral injection of Cu-Cy-I nanoparticles and X-ray radiotherapy enhanced the tumor growth-inhibitory effect and prolonged the mice’s lives. Conclusions: Cu-Cy-I nanoparticles have good potential as new radiosensitizers to enhance the efficacy of external X-ray radiotherapy. However, the efficacy of local treatment with [131I]Cu-Cy-I nanoparticles at a low 131I dose was not verified. The effective synthesis of smaller sizes of nanoparticles is necessary for further investigation of the radiotherapy potential of [131I]Cu-Cy-I nanoparticles.
Background/Objectives: Radiotherapy is a widely applied first-line clinical treatment modality of cancer. Copper-cysteamine (Cu-Cy) nanoparticles represent a new type of photosensitizer that demonstrates significant anti-tumor potential by X-ray-induced photodynamic therapy. Iodide is a high-Z element with superior X-ray absorption ability and has the β-decay radiotherapeutic nuclide, 131I, which emits Cherenkov light. In this study we aimed to investigate the X-ray-induced photodynamic therapy potential of iodinated Cu-Cy (Cu-Cy-I) nanoparticles and also explore the local treatment efficacy of 131I-labeled Cu-Cy-I ([131I]Cu-Cy-I) nanoparticles. Methods: The synthesis of [131I]Cu-Cy-I nanoparticles was performed with [131I]I- anions. The in vitro radiobiological effects on tumor cells incubated with Cu-Cy-I nanoparticles by X-ray irradiation were investigated. The in vivo tumor growth-inhibitory effects of the combination of Cu-Cy-I nanoparticles with X-ray radiotherapy and [131I]Cu-Cy-I nanoparticles were evaluated with 4T1 tumor-xenografted mice. Results: The in vitro experiment results indicated that the X-ray irradiation with the presence of Cu-Cy-I nanoparticles produced a higher intracellular reactive oxygen species (ROS) level and more DNA damage of 4T1 cells and showed a stronger tumor cell killing ability compared to X-ray irradiation alone. The in vivo experimental results with 4T1 breast carcinoma-bearing mice showed that the combination of an intratumoral injection of Cu-Cy-I nanoparticles and X-ray radiotherapy enhanced the tumor growth-inhibitory effect and prolonged the mice's lives. Conclusions: Cu-Cy-I nanoparticles have good potential as new radiosensitizers to enhance the efficacy of external X-ray radiotherapy. However, the efficacy of local treatment with [131I]Cu-Cy-I nanoparticles at a low 131I dose was not verified. The effective synthesis of smaller sizes of nanoparticles is necessary for further investigation of the radiotherapy potential of [131I]Cu-Cy-I nanoparticles.Background/Objectives: Radiotherapy is a widely applied first-line clinical treatment modality of cancer. Copper-cysteamine (Cu-Cy) nanoparticles represent a new type of photosensitizer that demonstrates significant anti-tumor potential by X-ray-induced photodynamic therapy. Iodide is a high-Z element with superior X-ray absorption ability and has the β-decay radiotherapeutic nuclide, 131I, which emits Cherenkov light. In this study we aimed to investigate the X-ray-induced photodynamic therapy potential of iodinated Cu-Cy (Cu-Cy-I) nanoparticles and also explore the local treatment efficacy of 131I-labeled Cu-Cy-I ([131I]Cu-Cy-I) nanoparticles. Methods: The synthesis of [131I]Cu-Cy-I nanoparticles was performed with [131I]I- anions. The in vitro radiobiological effects on tumor cells incubated with Cu-Cy-I nanoparticles by X-ray irradiation were investigated. The in vivo tumor growth-inhibitory effects of the combination of Cu-Cy-I nanoparticles with X-ray radiotherapy and [131I]Cu-Cy-I nanoparticles were evaluated with 4T1 tumor-xenografted mice. Results: The in vitro experiment results indicated that the X-ray irradiation with the presence of Cu-Cy-I nanoparticles produced a higher intracellular reactive oxygen species (ROS) level and more DNA damage of 4T1 cells and showed a stronger tumor cell killing ability compared to X-ray irradiation alone. The in vivo experimental results with 4T1 breast carcinoma-bearing mice showed that the combination of an intratumoral injection of Cu-Cy-I nanoparticles and X-ray radiotherapy enhanced the tumor growth-inhibitory effect and prolonged the mice's lives. Conclusions: Cu-Cy-I nanoparticles have good potential as new radiosensitizers to enhance the efficacy of external X-ray radiotherapy. However, the efficacy of local treatment with [131I]Cu-Cy-I nanoparticles at a low 131I dose was not verified. The effective synthesis of smaller sizes of nanoparticles is necessary for further investigation of the radiotherapy potential of [131I]Cu-Cy-I nanoparticles.
Radiotherapy is a widely applied first-line clinical treatment modality of cancer. Copper-cysteamine (Cu-Cy) nanoparticles represent a new type of photosensitizer that demonstrates significant anti-tumor potential by X-ray-induced photodynamic therapy. Iodide is a high-Z element with superior X-ray absorption ability and has the β-decay radiotherapeutic nuclide, I, which emits Cherenkov light. In this study we aimed to investigate the X-ray-induced photodynamic therapy potential of iodinated Cu-Cy (Cu-Cy-I) nanoparticles and also explore the local treatment efficacy of I-labeled Cu-Cy-I ([ I]Cu-Cy-I) nanoparticles. : The synthesis of [ I]Cu-Cy-I nanoparticles was performed with [ I]I anions. The in vitro radiobiological effects on tumor cells incubated with Cu-Cy-I nanoparticles by X-ray irradiation were investigated. The in vivo tumor growth-inhibitory effects of the combination of Cu-Cy-I nanoparticles with X-ray radiotherapy and [ I]Cu-Cy-I nanoparticles were evaluated with 4T1 tumor-xenografted mice. : The in vitro experiment results indicated that the X-ray irradiation with the presence of Cu-Cy-I nanoparticles produced a higher intracellular reactive oxygen species (ROS) level and more DNA damage of 4T1 cells and showed a stronger tumor cell killing ability compared to X-ray irradiation alone. The in vivo experimental results with 4T1 breast carcinoma-bearing mice showed that the combination of an intratumoral injection of Cu-Cy-I nanoparticles and X-ray radiotherapy enhanced the tumor growth-inhibitory effect and prolonged the mice's lives. : Cu-Cy-I nanoparticles have good potential as new radiosensitizers to enhance the efficacy of external X-ray radiotherapy. However, the efficacy of local treatment with [ I]Cu-Cy-I nanoparticles at a low I dose was not verified. The effective synthesis of smaller sizes of nanoparticles is necessary for further investigation of the radiotherapy potential of [ I]Cu-Cy-I nanoparticles.
Background/Objectives: Radiotherapy is a widely applied first-line clinical treatment modality of cancer. Copper–cysteamine (Cu-Cy) nanoparticles represent a new type of photosensitizer that demonstrates significant anti-tumor potential by X-ray-induced photodynamic therapy. Iodide is a high-Z element with superior X-ray absorption ability and has the β-decay radiotherapeutic nuclide, 131 I, which emits Cherenkov light. In this study we aimed to investigate the X-ray-induced photodynamic therapy potential of iodinated Cu-Cy (Cu-Cy-I) nanoparticles and also explore the local treatment efficacy of 131 I-labeled Cu-Cy-I ([ 131 I]Cu-Cy-I) nanoparticles. Methods : The synthesis of [ 131 I]Cu-Cy-I nanoparticles was performed with [ 131 I]I − anions. The in vitro radiobiological effects on tumor cells incubated with Cu-Cy-I nanoparticles by X-ray irradiation were investigated. The in vivo tumor growth-inhibitory effects of the combination of Cu-Cy-I nanoparticles with X-ray radiotherapy and [ 131 I]Cu-Cy-I nanoparticles were evaluated with 4T1 tumor-xenografted mice. Results : The in vitro experiment results indicated that the X-ray irradiation with the presence of Cu-Cy-I nanoparticles produced a higher intracellular reactive oxygen species (ROS) level and more DNA damage of 4T1 cells and showed a stronger tumor cell killing ability compared to X-ray irradiation alone. The in vivo experimental results with 4T1 breast carcinoma-bearing mice showed that the combination of an intratumoral injection of Cu-Cy-I nanoparticles and X-ray radiotherapy enhanced the tumor growth-inhibitory effect and prolonged the mice’s lives. Conclusions : Cu-Cy-I nanoparticles have good potential as new radiosensitizers to enhance the efficacy of external X-ray radiotherapy. However, the efficacy of local treatment with [ 131 I]Cu-Cy-I nanoparticles at a low 131 I dose was not verified. The effective synthesis of smaller sizes of nanoparticles is necessary for further investigation of the radiotherapy potential of [ 131 I]Cu-Cy-I nanoparticles.
Author Xu, Ying
Li, Shihong
Zhang, Miaomiao
Yang, Yu
Wang, Jie
AuthorAffiliation 3 Institute for Advanced Materials, School of Material Science and Engineering, Jiangsu University, Zhenjiang 212013, China; wangjie@ujs.edu.cn
2 Department of Clinical Pharmacology, The First Affiliated Hospital of Soochow University, Suzhou 215006, China
1 State Key Laboratory of Radiation Medicine and Protection, School of Radiation Medicine and Protection, Suzhou Medical College of Soochow University, Suzhou 215123, China; 20224220061@stu.suda.edu.cn (M.Z.); yangyu6335@126.com (Y.Y.); 20224020015@stu.suda.edu.cn (Y.X.)
AuthorAffiliation_xml – name: 3 Institute for Advanced Materials, School of Material Science and Engineering, Jiangsu University, Zhenjiang 212013, China; wangjie@ujs.edu.cn
– name: 1 State Key Laboratory of Radiation Medicine and Protection, School of Radiation Medicine and Protection, Suzhou Medical College of Soochow University, Suzhou 215123, China; 20224220061@stu.suda.edu.cn (M.Z.); yangyu6335@126.com (Y.Y.); 20224020015@stu.suda.edu.cn (Y.X.)
– name: 2 Department of Clinical Pharmacology, The First Affiliated Hospital of Soochow University, Suzhou 215006, China
Author_xml – sequence: 1
  givenname: Miaomiao
  surname: Zhang
  fullname: Zhang, Miaomiao
– sequence: 2
  givenname: Yu
  surname: Yang
  fullname: Yang, Yu
– sequence: 3
  givenname: Ying
  surname: Xu
  fullname: Xu, Ying
– sequence: 4
  givenname: Jie
  orcidid: 0000-0003-3150-6947
  surname: Wang
  fullname: Wang, Jie
– sequence: 5
  givenname: Shihong
  orcidid: 0000-0003-4047-2988
  surname: Li
  fullname: Li, Shihong
BackLink https://www.ncbi.nlm.nih.gov/pubmed/40006516$$D View this record in MEDLINE/PubMed
BookMark eNptks1u1DAQgCNUREvpI4AiceGyYGecxD4htOJnpQokVLhaY3vc9WoTBztBWk68A2_Ik5DuLlWL8MEeez59HtnzuDjpY09F8ZSzlwCKvRrWmDq0NI3BZt6yinGhHhRnXCm1EKqCkzvxaXGR84bNA4BLUI-KUzFvmpo3Z8XXVXShx5FcuYzDQOn3z1_LXR4Ju9BT-RH7OGCar9lSLjGXn9GFmKnPYQw_KOXSx1ReTd0871PjmhIOuyfFQ4_bTBfH9bz48u7t1fLD4vLT-9XyzeXCilqMi5Yx6blyQrS28pXzigRDqWytRM2kZYitawSDRtUGBYC10JBRSBy8QYTzYnXwuogbPaTQYdrpiEHvD2K61sfqNTMADDwwZ5ww5I2S6Ik55701poLZ9frgGibTkbPUjwm396T3M31Y6-v4XXMua6kqNRteHA0pfpsoj7oL2dJ2iz3FKWvgLQfJZVvP6PN_0E2cUj-_1Z7irWzhRvjsbkm3tfz9vxmoD4BNMedE_hbhTN-0iv5vq8AfXF64Yg
Cites_doi 10.1039/D3CC01355C
10.1007/s11307-011-0489-z
10.1186/s13046-018-0758-7
10.3389/fbioe.2022.920162
10.1016/j.pdpdt.2023.103816
10.1038/s41571-022-00697-z
10.1002/adhm.202000802
10.1039/C9CP04392F
10.1016/j.msec.2020.110659
10.1038/s41598-017-09375-y
10.1002/anie.202107231
10.1016/j.bbcan.2019.07.003
10.1021/acsnano.3c05853
10.1016/S2214-109X(24)00355-3
10.1111/j.1751-1097.2009.00558.x
10.1038/nnano.2015.17
10.1039/C9TB01566C
10.1088/0031-9155/41/10/004
10.2147/IJN.S362759
10.1007/978-1-60761-411-1_4
10.1088/0031-9155/60/17/6701
10.1002/adma.201904894
10.1038/s41392-020-0156-4
10.1517/17425247.2016.1167035
10.1166/jbn.2014.1954
10.1021/acs.bioconjchem.4c00334
10.1021/jp4077189
10.3390/radiation1010002
10.1016/j.mtphys.2021.100435
10.7150/thno.75279
10.1039/c8pp00112j
10.1016/j.addr.2017.01.004
10.1021/acsnano.3c00891
10.1039/C4TC00114A
10.1007/978-3-031-04071-9
10.3390/nano10061087
10.1038/nnano.2011.166
ContentType Journal Article
Copyright 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2025 by the authors. 2025
Copyright_xml – notice: 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2025 by the authors. 2025
DBID AAYXX
CITATION
NPM
3V.
7XB
8FK
8G5
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
GNUQQ
GUQSH
M2O
MBDVC
PHGZM
PHGZT
PIMPY
PKEHL
PQEST
PQQKQ
PQUKI
PRINS
Q9U
7X8
5PM
DOA
DOI 10.3390/pharmaceutics17020149
DatabaseName CrossRef
PubMed
ProQuest Central (Corporate)
ProQuest Central (purchase pre-March 2016)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Research Library
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One
ProQuest Central Korea
ProQuest Central Student
Research Library Prep
Research Library
Research Library (Corporate)
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
Publicly Available Content Database
Research Library Prep
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Basic
ProQuest Central Essentials
ProQuest One Academic Eastern Edition
ProQuest Central (Alumni Edition)
ProQuest One Community College
Research Library (Alumni Edition)
ProQuest Central China
ProQuest Central
ProQuest One Academic UKI Edition
ProQuest Central Korea
ProQuest Research Library
ProQuest Central (New)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList Publicly Available Content Database
MEDLINE - Academic
CrossRef
PubMed


Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1999-4923
ExternalDocumentID oai_doaj_org_article_0b3303f30dbd4befb98afe0ddffcbb23
PMC11858929
40006516
10_3390_pharmaceutics17020149
Genre Journal Article
GrantInformation_xml – fundername: National Natural Science Foundation of China
  grantid: 12175163
GroupedDBID ---
53G
5VS
8G5
AADQD
AAYXX
ABDBF
ABUWG
ACGFO
ACIHN
ACUHS
AEAQA
AFKRA
AFZYC
ALMA_UNASSIGNED_HOLDINGS
AZQEC
BENPR
BPHCQ
CCPQU
CITATION
DIK
DWQXO
EBD
ESX
F5P
FD6
GNUQQ
GROUPED_DOAJ
GUQSH
GX1
HH5
HYE
IAO
IHR
ITC
KQ8
M2O
M48
MK0
MODMG
M~E
OK1
P6G
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
RNS
RPM
TR2
TUS
3V.
NPM
7XB
8FK
MBDVC
PKEHL
PQEST
PQUKI
PRINS
Q9U
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c454t-7008f19d447c2f2df9e40a89c594508c0aa7d6403695ba433cc36eb9ae13fbaa3
IEDL.DBID M48
ISSN 1999-4923
IngestDate Wed Aug 27 01:32:44 EDT 2025
Thu Aug 21 18:27:43 EDT 2025
Thu Jul 10 22:05:40 EDT 2025
Mon Jun 30 12:12:35 EDT 2025
Sat Mar 01 01:25:39 EST 2025
Tue Jul 01 00:37:20 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 2
Keywords radiotherapy
X-ray-induced photodynamic therapy
copper–cysteamine nanoparticles
131I
radiosensitization
Language English
License https://creativecommons.org/licenses/by/4.0
Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c454t-7008f19d447c2f2df9e40a89c594508c0aa7d6403695ba433cc36eb9ae13fbaa3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0003-4047-2988
0000-0003-3150-6947
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.3390/pharmaceutics17020149
PMID 40006516
PQID 3171178739
PQPubID 2032349
ParticipantIDs doaj_primary_oai_doaj_org_article_0b3303f30dbd4befb98afe0ddffcbb23
pubmedcentral_primary_oai_pubmedcentral_nih_gov_11858929
proquest_miscellaneous_3171381875
proquest_journals_3171178739
pubmed_primary_40006516
crossref_primary_10_3390_pharmaceutics17020149
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 20250122
PublicationDateYYYYMMDD 2025-01-22
PublicationDate_xml – month: 1
  year: 2025
  text: 20250122
  day: 22
PublicationDecade 2020
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
– name: Basel
PublicationTitle Pharmaceutics
PublicationTitleAlternate Pharmaceutics
PublicationYear 2025
Publisher MDPI AG
MDPI
Publisher_xml – name: MDPI AG
– name: MDPI
References Larue (ref_11) 2018; 17
Guo (ref_19) 2021; 60
Ma (ref_28) 2014; 2
Eruslanov (ref_31) 2010; 594
Yu (ref_14) 2019; 31
Glaser (ref_17) 2015; 60
Ran (ref_16) 2012; 14
ref_34
Tang (ref_20) 2018; 37
Daouk (ref_12) 2020; 1
Liu (ref_18) 2022; 12
Cabral (ref_37) 2011; 6
Emfietzoglou (ref_33) 2005; 46
ref_39
Zhu (ref_1) 2024; 12
Xu (ref_38) 2023; 17
Bulin (ref_10) 2013; 117
Zhang (ref_29) 2020; 5
Allen (ref_3) 2017; 109
Xiong (ref_7) 2024; 35
Goins (ref_35) 2016; 13
Overchuk (ref_8) 2023; 17
Rodriguez (ref_32) 2009; 85
ref_25
Wang (ref_27) 2021; 19
Vozenin (ref_2) 2022; 12
ref_24
ref_21
Kotagiri (ref_13) 2015; 10
Lioret (ref_15) 2023; 44
Wang (ref_9) 2021; 10
Ye (ref_5) 2022; 17
Zweit (ref_36) 1996; 41
Ma (ref_22) 2014; 10
Wei (ref_4) 2023; 59
ref_26
Alias (ref_30) 2019; 21
Pandey (ref_23) 2019; 7
ref_6
References_xml – volume: 59
  start-page: 6956
  year: 2023
  ident: ref_4
  article-title: Recent progress in metal complexes functionalized nanomaterials for photodynamic therapy
  publication-title: Chem. Commun.
  doi: 10.1039/D3CC01355C
– volume: 14
  start-page: 156
  year: 2012
  ident: ref_16
  article-title: In vivo photoactivation without “light”: Use of Cherenkov radiation to overcome the penetration limit of light
  publication-title: Mol. Imaging Biol.
  doi: 10.1007/s11307-011-0489-z
– volume: 37
  start-page: 87
  year: 2018
  ident: ref_20
  article-title: Role of metabolism in cancer cell radioresistance and radiosensitization methods
  publication-title: J. Exp. Clin. Cancer Res.
  doi: 10.1186/s13046-018-0758-7
– ident: ref_6
  doi: 10.3389/fbioe.2022.920162
– volume: 44
  start-page: 103816
  year: 2023
  ident: ref_15
  article-title: Cherenkov Radiation induced photodynamic therapy—Repurposing older photosensitizers, and radionuclides
  publication-title: Photodiagn. Photodyn. Ther.
  doi: 10.1016/j.pdpdt.2023.103816
– ident: ref_34
– volume: 12
  start-page: 791
  year: 2022
  ident: ref_2
  article-title: Towards clinical translation of FLASH radiotherapy
  publication-title: Nat. Rev. Clin. Oncol.
  doi: 10.1038/s41571-022-00697-z
– volume: 10
  start-page: e2000802
  year: 2021
  ident: ref_9
  article-title: Radioiodinated Persistent Luminescence Nanoplatform for Radiation-Induced Photodynamic Therapy and Radiotherapy
  publication-title: Adv. Healthc. Mater.
  doi: 10.1002/adhm.202000802
– volume: 21
  start-page: 21084
  year: 2019
  ident: ref_30
  article-title: Theoretical studies on the energy structures and optical properties of copper cysteamine—A novel sensitizer
  publication-title: Phys. Chem. Chem. Phys.
  doi: 10.1039/C9CP04392F
– ident: ref_24
  doi: 10.1016/j.msec.2020.110659
– ident: ref_26
  doi: 10.1038/s41598-017-09375-y
– volume: 60
  start-page: 21884
  year: 2021
  ident: ref_19
  article-title: Smart 131 I-Labeled Self-Illuminating Photosensitizers for Deep Tumor Therapy
  publication-title: Angew. Chem. Int. Ed. Engl.
  doi: 10.1002/anie.202107231
– ident: ref_39
  doi: 10.1016/j.bbcan.2019.07.003
– volume: 17
  start-page: 20825
  year: 2023
  ident: ref_38
  article-title: Size-Dependent In Vivo Transport of Nanoparticles: Implications for Delivery, Targeting, and Clearance
  publication-title: ACS Nano
  doi: 10.1021/acsnano.3c05853
– volume: 12
  start-page: e1945
  year: 2024
  ident: ref_1
  article-title: Global radiotherapy demands and corresponding radiotherapy-professional workforce requirements in 2022 and predicted to 2050: A population-based study
  publication-title: Lancet Glob. Health
  doi: 10.1016/S2214-109X(24)00355-3
– volume: 85
  start-page: 1189
  year: 2009
  ident: ref_32
  article-title: Structural factors and mechanisms underlying the improved photodynamic cell killing with silicon phthalocyanine photosensitizers directed to lysosomes versus mitochondria
  publication-title: Photochem. Photobiol.
  doi: 10.1111/j.1751-1097.2009.00558.x
– volume: 10
  start-page: 370
  year: 2015
  ident: ref_13
  article-title: Breaking the depth dependency of phototherapy with Cerenkov radiation and low-radiance-responsive nanophotosensitizers
  publication-title: Nat. Nanotechnol.
  doi: 10.1038/nnano.2015.17
– volume: 7
  start-page: 6630
  year: 2019
  ident: ref_23
  article-title: A facile method for the synthesis of copper-cysteamine nanoparticles and study of ROS production for cancer treatment
  publication-title: J. Mater. Chem. B
  doi: 10.1039/C9TB01566C
– volume: 41
  start-page: 1905
  year: 1996
  ident: ref_36
  article-title: Radionuclides and carrier molecules for therapy
  publication-title: Phys. Med. Biol.
  doi: 10.1088/0031-9155/41/10/004
– volume: 17
  start-page: 2367
  year: 2022
  ident: ref_5
  article-title: Recent Progress of Metal-Organic Framework-Based Photodynamic Therapy for Cancer Treatment
  publication-title: Int. J. Nanomed.
  doi: 10.2147/IJN.S362759
– volume: 594
  start-page: 57
  year: 2010
  ident: ref_31
  article-title: Identification of ROS using oxidized DCFDA and flow-cytometry
  publication-title: Methods Mol. Biol.
  doi: 10.1007/978-1-60761-411-1_4
– volume: 60
  start-page: 6701
  year: 2015
  ident: ref_17
  article-title: Cherenkov radiation fluence estimates in tissue for molecular imaging and therapy applications
  publication-title: Phys. Med. Biol.
  doi: 10.1088/0031-9155/60/17/6701
– volume: 46
  start-page: 89
  year: 2005
  ident: ref_33
  article-title: Liposome-mediated radiotherapeutics within avascular tumor spheroids: Comparative dosimetry study for various radionuclides, liposome systems, and a targeting antibody
  publication-title: J. Nucl. Med.
– volume: 31
  start-page: e1904894
  year: 2019
  ident: ref_14
  article-title: A “Missile-Detonation” Strategy to Precisely Supply and Efficiently Amplify Cerenkov Radiation Energy for Cancer Theranostics
  publication-title: Adv. Mater.
  doi: 10.1002/adma.201904894
– volume: 5
  start-page: 58
  year: 2020
  ident: ref_29
  article-title: Use of copper-cysteamine nanoparticles to simultaneously enable radiotherapy, oxidative therapy and immunotherapy for melanoma treatment
  publication-title: Signal Transduct. Target. Ther.
  doi: 10.1038/s41392-020-0156-4
– volume: 13
  start-page: 873
  year: 2016
  ident: ref_35
  article-title: Strategies for improving the intratumoral distribution of liposomal drugs in cancer therapy
  publication-title: Expert Opin. Drug Deliv.
  doi: 10.1517/17425247.2016.1167035
– volume: 10
  start-page: 1501
  year: 2014
  ident: ref_22
  article-title: A new X-ray activated nanoparticle photosensitizer for cancer treatment
  publication-title: J. Biomed. Nanotechnol.
  doi: 10.1166/jbn.2014.1954
– volume: 35
  start-page: 1269
  year: 2024
  ident: ref_7
  article-title: Development of a Self-Luminescent Living Bioreactor for Enhancing Photodynamic Therapy in Breast Cancer
  publication-title: Bioconjug. Chem.
  doi: 10.1021/acs.bioconjchem.4c00334
– volume: 117
  start-page: 21583
  year: 2013
  ident: ref_10
  article-title: X-ray-Induced Singlet Oxygen Activation with Nanoscintillator-Coupled Porphyrins
  publication-title: J. Phys. Chem. C
  doi: 10.1021/jp4077189
– volume: 1
  start-page: 5
  year: 2020
  ident: ref_12
  article-title: Can Cerenkov Light Really Induce an Effective Photodynamic Therapy?
  publication-title: Radiation
  doi: 10.3390/radiation1010002
– volume: 19
  start-page: 100435
  year: 2021
  ident: ref_27
  article-title: A new type of cuprous-cysteamine sensitizers: Synthesis, optical properties and potential applications
  publication-title: Mater. Today Phys.
  doi: 10.1016/j.mtphys.2021.100435
– volume: 12
  start-page: 7404
  year: 2022
  ident: ref_18
  article-title: Cerenkov radiation-activated probes for deep cancer theranostics: A review
  publication-title: Theranostics
  doi: 10.7150/thno.75279
– volume: 17
  start-page: 1612
  year: 2018
  ident: ref_11
  article-title: Using X-rays in photodynamic therapy: An overview
  publication-title: Photochem. Photobiol. Sci.
  doi: 10.1039/c8pp00112j
– volume: 109
  start-page: 1
  year: 2017
  ident: ref_3
  article-title: Radiotherapy for Cancer: Present and Future
  publication-title: Adv. Drug Deliv. Rev.
  doi: 10.1016/j.addr.2017.01.004
– volume: 17
  start-page: 7979
  year: 2023
  ident: ref_8
  article-title: Photodynamic and Photothermal Therapies: Synergy Opportunities for Nanomedicine
  publication-title: ACS Nano
  doi: 10.1021/acsnano.3c00891
– volume: 2
  start-page: 4239
  year: 2014
  ident: ref_28
  article-title: A new Cu–cysteamine complex: Structure and optical properties
  publication-title: J. Mater. Chem. C
  doi: 10.1039/C4TC00114A
– ident: ref_21
  doi: 10.1007/978-3-031-04071-9
– ident: ref_25
  doi: 10.3390/nano10061087
– volume: 6
  start-page: 815
  year: 2011
  ident: ref_37
  article-title: Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size
  publication-title: Nat. Nanotechnol.
  doi: 10.1038/nnano.2011.166
SSID ssj0000331839
Score 2.3426983
Snippet Background/Objectives: Radiotherapy is a widely applied first-line clinical treatment modality of cancer. Copper–cysteamine (Cu-Cy) nanoparticles represent a...
Radiotherapy is a widely applied first-line clinical treatment modality of cancer. Copper-cysteamine (Cu-Cy) nanoparticles represent a new type of...
Background/Objectives: Radiotherapy is a widely applied first-line clinical treatment modality of cancer. Copper-cysteamine (Cu-Cy) nanoparticles represent a...
Background/Objectives: Radiotherapy is a widely applied first-line clinical treatment modality of cancer. Copper–cysteamine (Cu-Cy) nanoparticles represent a...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
StartPage 149
SubjectTerms 131I
Biotechnology
Cancer therapies
Copper
copper–cysteamine nanoparticles
Light
Nanoparticles
Ovarian cancer
Photodynamic therapy
Polyvinyl alcohol
Radiation therapy
Radioactivity
radiosensitization
radiotherapy
Reactive oxygen species
Tumors
X-ray-induced photodynamic therapy
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LT9wwELYQp14QUB4ptDIS4kRKHDsPH9tVEa0EQmipuEXjl9gDyYrsHpYT_4F_2F_ScRz2USH1wiWH2FIcz9jzfcnMZ0KONeMI8zUuJFHyWHjxWSiSLM6VcTwDzyh87fDlVX5xK37dZXdLR335nLAgDxwm7ixRyLi544lRRijrlCzB2cQY57RSaafziTFviUx1ezD3vipDyQ5HXn82vl98Im5ZgSiJef3MpWDUafa_BTT_zZdcCkDnm2SjR470WxjxFlmz9TY5uQ4PnJ3S4aKSqj2lJ_R6IUo9-0h-_2wwSiGwNHTQjMf28c_zy8CrOMMD4kyKmyyy5z5JjkJLb8CMmtZnt09GTwgRKYJbOpw-4LVrCnVbsx1ye_5jOLiI-zMVYi0yMYkLjPmOSSNEoVOXGietSKCUOpMCsZpOAAqTC4xrMlMgONea51ZJsIw7BcB3yXrd1HafUOaQy4GSNle50IkuNfdyckxZAC8uGpGvr5NbjYN0RoWUw1ujetMaEfnuTTDv7JWvuxvoD1U_BdX__CEih68GrPrl2FYIkhjDrYnjM47mzbiQ_N8RqG0zDX08fCmyiOwFe89HIjqoxvKIlCuesDLU1ZZ6dN-JdSOBy0rEoJ_e4-UOyIfUnz-csDhND8n65HFqPyMomqgvnf__Bft9EwY
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: ProQuest Central
  dbid: BENPR
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwEB7B9sIF8SZQkJFQTw2NY-fhE6KrVgWJalVtUW-Rn3QPTcJm97Cc-A_8Q34J48S720UVlxxiS7Ey45lv7JlvAN5ryhDma9xIvGQx9-SzskiyOFfGsUz6iMLXDn89z88u-Zer7CocuHUhrXJtE3tDbRrtz8iP0M9RitrFxMf2R-y7Rvnb1dBC4z7soQkuyxHsHZ-cTy42pywJ8zorhtIdhvH9UXu9PSruaIFoiXoezVtOqefuvwtw_ps3ecsRnT6ChwFBkk-DyB_DPVs_gYPJ8MHVIZluK6q6Q3JAJlty6tVT-Pa5QW-FANOQcdO2dv7n1--xZ3OWN4g3CRpbjKJDshyRHbmQZtZ0Pst9MfuJUJEgyCXT5Q0--6Ghfmv1DC5PT6bjszj0Vog1z_giLtD3OyoM54VOXWqcsDyRpdCZ4IjZdCJlYXKO_k1kSnLGtGa5VUJaypySkj2HUd3U9iUQ6jCmk0rYXOVcJ7rUzNPKUWWl9CSjEXxY_9yqHSg0Kgw9vDSqO6URwbEXwWayZ8DuXzTz71X4BVWiGHpfxxKjDFfWKVFKZxNjnNNKpSyC_bUAq7Atu2qrRBG82wzjhvK3JLK2zXKY42FMkUXwYpD3ZiW8h2w0j6Dc0YSdpe6O1LPrnrQbA7msRCz66v_reg0PUt9hOKFxmu7DaDFf2jcIexbqbdDtvwK5CWY
  priority: 102
  providerName: ProQuest
Title Iodinated Copper–Cysteamine Nanoparticles as Radiosensitizers for Tumor Radiotherapy
URI https://www.ncbi.nlm.nih.gov/pubmed/40006516
https://www.proquest.com/docview/3171178739
https://www.proquest.com/docview/3171381875
https://pubmed.ncbi.nlm.nih.gov/PMC11858929
https://doaj.org/article/0b3303f30dbd4befb98afe0ddffcbb23
Volume 17
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjZ3fa9swEMePrn3Zy-h-u-2CBqNPdWdZ8g89lLKGlm7QEkoCfTP6uQZWO40TWPbX72Q7yTIy2EseImMZ3Un3OVv6HsAnTRlivsaJxHMWci8-K7MoCVNlHEukzyj82eGb2_R6xL_dJ_c7sBRU6Aaw3pra-XpSo-mP059Pi3Oc8Gc-48SU_fPkYf32t6YZAhBi_zPYw-CU-aIGNx3xN4sz804smm_NwtdXi1l7ruffd9qIWI2w_zYa_XtT5R9R6mofXnR4Sb60_vASdmz5Co4HbYeLEzJcH7eqT8gxGayVqxevYfi1wlCG9GlIv5pM7DTse6Fn-YgoSnAdxgS720dHZE3upBlXtd8APxv_QookyL9kOH_E36apPdq1eAOjq8th_zrsyi6Emid8FmaIBY4Kw3mmYxcbJyyPZC50IjjinI6kzEzKMfSJREnOmNYstUpIS5lTUrK3sFtWpX0PhDpM96QSNlUp15HONfOKc1RZKb3-aACny6EtJq26RoFZibdFsdUWAVx4A6wu9uLYzR_V9HvRDUERKYaB2bHIKMOVdUrk0tnIGOe0UjEL4GhpvmLpcAVyFKW4ejHs4-OqGeea_4AiS1vN22s84WRJAO9aa6-ehDc0R9MA8g0_2HjUzZZy_NDoeWOOl-SIqQf_0fEhPI99BeKIhnF8BLuz6dx-QCyaqR7sXVzeDu56zWuFXuP2vwHdhxMZ
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3NbtNAEB6V9AAXxD-GAosEPdXU613_HRCioVVC2yiqUtSbu780h8YhToTCiXfgPXgonoRZ20kaVHHrxQfvyl7vzM58s975BuCNogxhvsKFxFPmc0c-K5Ig8mOpLYuEiyhc7vBxL-6c8s9n0dkG_F7kwrhjlQubWBlqXSi3R76Lfo5S1C6WfRh_813VKPd3dVFCo1aLQzP_jiFb-b77CeX7NgwP9gftjt9UFfAVj_jUT9DrWZppzhMV2lDbzPBApJmKMo5oRQVCJDrmaNmzSArOmFIsNjIThjIrhWD43FuwyfEbwxZs7u33-ifLXZ2AuTWS1alCjGXB7vhitTVd0gTRGXW8nVecYFUr4DqA--85zSuO7-Ae3G0QK_lYq9h92DCjB7Ddr1843yGDVQZXuUO2SX9Fhj1_CF-6BXpHBLSatIvx2Ez-_PzVduzR4hLxLUHjjlF7cziPiJKcCD0sSneqfjr8gdCUIKgmg9klXqumOl9s_ghOb2TWH0NrVIzMUyDUYgwpZGZiGXMVqFQxR2NHpRHCkZp68G4xufm4puzIMdRx0sivlYYHe04Ey86Ocbu6UUy-5s0U5IFk6O0tC7TUXBors1RYE2htrZIyZB5sLQSYN2agzFdK68HrZTMuYPdXRoxMMav7ONiURB48qeW9HAmvICKNPUjXNGFtqOsto-FFRRKOgWOUIvZ99v9xvYLbncHxUX7U7R0-hzuhq24cUD8Mt6A1nczMC4RcU_my0XMC5ze9tP4CakhGYQ
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEB6VVEJcEG8MBRYJeqqJ17t-HRCiaaOGQhRVKerN7JPm0DjEiVA48R_4N_wcfgmztpM0qOLWSw5ZK1ntvL5Zz3wD8EpRhjBfoSHxlPnckc-KJIj8WGrLIuEyCtc7_KkfH53yD2fR2Rb8XvbCuLLKpU-sHLUulLsjb2OcoxS1i2Vt25RFDA667ybffDdByr1pXY7TqFXk2Cy-Y_pWvu0doKxfh2H3cNg58psJA77iEZ_5CUZASzPNeaJCG2qbGR6INFNRxhG5qECIRMccvXwWScEZU4rFRmbCUGalEAx_9wZsJy4rasH2_mF_cLK64QmYs5esbhtiLAvak_P1NXVJE0Rq1HF4XgqI1dyAq8DuvzWbl4Jg9w7cbtAreV-r213YMuN7sDuo_3CxR4brbq5yj-ySwZoYe3EfPvcKjJQIbjXpFJOJmf75-avjmKTFBWJdgo4eM_imUI-IkpwIPSpKV2E_G_1AmEoQYJPh_AI_q6W6d2zxAE6v5dQfQmtcjM1jINRiPilkZmIZcxWoVDFHaUelEcIRnHrwZnm4-aSm78gx7XHSyK-Uhgf7TgSrhx37dvVFMf2aN0eQB5Jh5Lcs0FJzaazMUmFNoLW1SsqQebCzFGDeuIQyXyuwBy9Xy2jM7g2NGJtiXj_jIFQSefColvdqJ7yCizT2IN3QhI2tbq6MR-cVYTgmkVGKOPjJ__f1Am6iSeUfe_3jp3ArdIOOA-qH4Q60ZtO5eYboayafN2pO4Mt1W9ZfHU5Klg
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Iodinated+Copper-Cysteamine+Nanoparticles+as+Radiosensitizers+for+Tumor+Radiotherapy&rft.jtitle=Pharmaceutics&rft.au=Zhang%2C+Miaomiao&rft.au=Yang%2C+Yu&rft.au=Xu%2C+Ying&rft.au=Wang%2C+Jie&rft.date=2025-01-22&rft.issn=1999-4923&rft.eissn=1999-4923&rft.volume=17&rft.issue=2&rft_id=info:doi/10.3390%2Fpharmaceutics17020149&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1999-4923&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1999-4923&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1999-4923&client=summon